Formulation Development
Opus Genetics Receives Rare Pediatric Disease Designation for Ocular Gene Therapy
Opus Genetics recently announced the US FDA has granted Rare Pediatric Disease designation (RPD) for its ocular gene therapy OPGx-LCA5 to treat patients with the…
ImmuneSensor Therapeutics Receives Clearance to Initiate First-in-Human Phase 1 Clinical Trial of cGAS inhibitor Drug Candidate
ImmuneSensor Therapeutics recently announced it has received Human Research Ethics Committee (HREC) approval and Clinical Trial Notification (CTN) clearance by the Australian Therapeutic Goods Administration…
Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri
Processa Pharmaceuticals, Inc. recently announced positive data from preclinical studies that support the potential for NGC-Iri to have improved efficacy and a better side effect…
Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial for Treatment of Patients With Glioblastoma
Shuttle Pharmaceuticals Holdings, Inc. recently announced it has entered into agreements with two of the six site locations to administer the Phase 2 clinical trial…
Nanoform Collaborates With Takeda on Plasma-Derived Therapy Development
Nanoform Finland Plc recently announced it is to enter into a pre-clinical development agreement with the Plasma-derived Therapies Business Unit of Takeda Pharmaceuticals, Inc., the…
Abata Therapeutics Announces Strategic Investment From Bristol Myers Squibb
Abata Therapeutics recently announced it has received an equity investment from Bristol Myers Squibb to support the development of its Treg cell therapy products. Their…
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
TransCode Therapeutics, Inc. recently announced initiation of its Phase 1 multicenter, open-label, clinical study of its lead therapeutic candidate, TTX-MC138. Two clinical trial sites have…
Denali Therapeutics Announces Publication Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS & Muscle Following Intravenous Administration
Denali Therapeutics Inc. recently announced publication of nonclinical data in the August 14, 2024, issue of Science Translational Medicine (link) demonstrating the ability of the…
Nuntius Therapeutics Announces Collaboration With Taiho Pharmaceutical to Develop Next-Generation mRNA Therapies Using Nuntius’ Proprietary Cell-Specific Delivery Technology
Nuntius Therapeutics recently announced it has entered into a collaboration agreement with Taiho Pharmaceutical Co., Ltd., a leading company in Japan for developing innovative medicines…
Prota Therapeutics Announces Publication of Long-Term Peanut Allergy Study Confirming Clinical Remission as the Optimal Treatment Outcome
Prota Therapeutics Pty Ltd recently announced publication in the journal Allergy of the first long-term study directly comparing remission and desensitization endpoints following food allergen…
Nykode Therapeutics Announces Issuance of Key Patent Covering Individualized Neoantigen Based Vaccines
Nykode Therapeutics ASA recently announced the United States Patent and Trademark Office (USPTO) has issued US Patent No. 12,059,459 titled Therapeutic Anticancer Neoepitope Vaccine. The…
Veralox Therapeutics Announces EMA Orphan Drug Designation
Veralox Therapeutics recently announced the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to VLX-1005, a small molecule 12-LOX inhibitor for the treatment…
Immutep Announces First Participant Dosed in Phase 1 Study of First in Class Agonist LAG-3 Antibody
Immutep Limited recently announced the first participant has been successfully dosed in the first-in-human Phase 1 trial of IMP761. This first-in-class agonist LAG-3 antibody is…
Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial
Monopar Therapeutics Inc. recently announced the successful dosing of the first patient in its open-label Phase 1 imaging and dosimetry clinical trial of its uPAR-targeted…
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients With Non-CNS MET Fusion Solid Tumors From its Phase 2 Trial
Apollomics Inc. recently announced positive preliminary clinical data for the cohort of patients with non-CNS MET fusion solid tumors from the Phase 2 SPARTA trial…
Evonik Expands its Formulation Capabilities for Lipid Nanoparticles Used for mRNA & Gene Therapies
Evonik is collaborating with KNAUER Wissenschaftliche Geräte GmbH, a manufacturer of scientific instruments, to improve the upscaling of lipid nanoparticle (LNP) formulations. By combining Evonik’s…
Purdue & Akston Biosciences Sign Partnership Agreement for Dog Cancer Drug Development
Akston Biosciences Corporation and Purdue University recently announced a strategic partnership to co-develop an anti-cPD-L1 monoclonal antibody (mAb) immunotherapy to treat cancer in dogs. The underlying…
Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial
Lipella Pharmaceuticals Inc. recently announced the dosing of the first two patients with LP-310 in its Phase 2a clinical trial in Oral Lichen Planus (OLP)…
Eclipse Life Sciences Initiates Phase 2 Study for Novel Ophthalmology Steroid Implant for Diabetic Macular Edema
Eclipse Life Sciences, Inc. recently announced it has enrolled and dosed its first patient in the BETTIS-1 Phase 2 clinical trial (NCT06536491) for EC-104 fluocinolone…
MBX Biosciences Doses First Patient in Phase 2 Avail Trial for the Treatment of Hypoparathyroidism
MBX Biosciences, Inc. recently it has dosed the first patient in its Phase 2 Avail trial of MBX 2109, the company’s parathyroid hormone (PTH) peptide…
